{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:10:09Z","timestamp":1790021409188,"version":"4.0.1"},"reference-count":218,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation, Korea","doi-asserted-by":"crossref","award":["NRF-2019R1A2C1084232"],"award-info":[{"award-number":["NRF-2019R1A2C1084232"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation, Korea","doi-asserted-by":"crossref","award":["NRF-2019R1A4A2001609"],"award-info":[{"award-number":["NRF-2019R1A4A2001609"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation, Korea","doi-asserted-by":"crossref","award":["NRF-2017M3C7A1026959"],"award-info":[{"award-number":["NRF-2017M3C7A1026959"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation, Korea","doi-asserted-by":"crossref","award":["NRF-2016H1A2A1907206"],"award-info":[{"award-number":["NRF-2016H1A2A1907206"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Brain"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The RAS signaling pathway is involved in the regulation of developmental processes, including cell growth, proliferation, and differentiation, in the central nervous system (CNS). Germline mutations in the RAS signaling pathway genes are associated with a group of neurodevelopmental disorders, collectively called RASopathy, which includes neurofibromatosis type 1, Noonan syndrome, cardio-facio-cutaneous syndrome, and Costello syndrome. Most mutations associated with RASopathies increase the activity of the RAS-ERK signaling pathway, and therefore, most individuals with RASopathies share common phenotypes, such as a short stature, heart defects, facial abnormalities, and cognitive impairments, which are often accompanied by abnormal CNS development. Recent studies using mouse models of RASopathies demonstrated that particular mutations associated with each disorder disrupt CNS development in a mutation-specific manner. Here, we reviewed the recent literatures that investigated the developmental role of RASopathy-associated mutations using mutant mice, which provided insights into the specific contribution of RAS-ERK signaling molecules to CNS development and the subsequent impact on cognitive function in adult mice.<\/jats:p>","DOI":"10.1186\/s13041-019-0517-5","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T14:03:34Z","timestamp":1574345014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["The impact of RASopathy-associated mutations on CNS development in mice and humans"],"prefix":"10.1186","volume":"12","author":[{"given":"Minkyung","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6217-9574","authenticated-orcid":false,"given":"Yong-Seok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"Pt 2","key":"517_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1042\/bj3510289","volume":"351","author":"W Kolch","year":"2000","unstructured":"Kolch W. Meaningful relationships: the regulation of the Ras\/Raf\/MEK\/ERK pathway by protein interactions. Biochem J. 2000;351(Pt 2):289\u2013305.","journal-title":"Biochem J"},{"key":"517_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/366643a0","volume":"366","author":"MS Boguski","year":"1993","unstructured":"Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature. 1993;366:643\u201354.","journal-title":"Nature."},{"key":"517_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.nlm.2016.06.006","volume":"135","author":"Hyun-Hee Ryu","year":"2016","unstructured":"Ryu HH, Lee YS. Cell type-specific roles of RAS-MAPK signaling in learning and memory: Implications in neurodevelopmental disorders. Neurobiol Learn Mem. 2016;135:13\u201321.","journal-title":"Neurobiology of Learning and Memory"},{"key":"517_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","volume":"14","author":"KA Rauen","year":"2013","unstructured":"Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet. 2013;14:355\u201369.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"517_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1083\/jcb.200108035","volume":"156","author":"M Innocenti","year":"2002","unstructured":"Innocenti M, Tenca P, Frittoli E, Faretta M, Tocchetti A, Di Fiore PP, Scita G. Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. J Cell Biol. 2002;156:125\u201336.","journal-title":"J Cell Biol"},{"key":"517_CR6","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1523\/JNEUROSCI.23-10-04228.2003","volume":"23","author":"L Zhao","year":"2003","unstructured":"Zhao L, Brinton RD. Vasopressin-induced cytoplasmic and nuclear calcium signaling in embryonic cortical astrocytes: dynamics of calcium and calcium-dependent kinase translocation. J Neurosci. 2003;23:4228\u201339.","journal-title":"J Neurosci"},{"key":"517_CR7","doi-asserted-by":"publisher","first-page":"4426","DOI":"10.1093\/emboj\/17.15.4426","volume":"17","author":"M Deak","year":"1998","unstructured":"Deak M, Clifton AD, Lucocq LM, Alessi DR. Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2\/p38, and may mediate activation of CREB. EMBO J. 1998;17:4426\u201341.","journal-title":"EMBO J"},{"key":"517_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1146\/annurev-neuro-060909-153215","volume":"33","author":"C Shilyansky","year":"2010","unstructured":"Shilyansky C, Lee YS, Silva AJ. Molecular and cellular mechanisms of learning disabilities: a focus on NF1. Annu Rev Neurosci. 2010;33:221\u201343.","journal-title":"Annu Rev Neurosci"},{"key":"517_CR9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.14348\/molcells.2019.0037","volume":"42","author":"YE Kim","year":"2019","unstructured":"Kim YE, Baek ST. Neurodevelopmental Aspects of RASopathies. Mol Cells. 2019;42:441\u20137.","journal-title":"Mol Cells"},{"key":"517_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.gde.2009.04.001","volume":"19","author":"WE Tidyman","year":"2009","unstructured":"Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras\/MAPK pathway dysregulation. Curr Opin Genet Dev. 2009;19:230\u20136.","journal-title":"Curr Opin Genet Dev"},{"key":"517_CR11","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1242\/dmm.020339","volume":"8","author":"GA Jindal","year":"2015","unstructured":"Jindal GA, Goyal Y, Burdine RD, Rauen KA, Shvartsman SY. RASopathies: unraveling mechanisms with animal models. Dis Model Mech. 2015;8:769\u201382.","journal-title":"Dis Model Mech"},{"key":"517_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1136\/jmg.2006.045906","volume":"44","author":"RE Ferner","year":"2007","unstructured":"Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG, Upadhyaya M, Towers R, Gleeson M, Steiger C, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44:81\u20138.","journal-title":"J Med Genet"},{"key":"517_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/brain\/90.4.829","volume":"90","author":"NP Rosman","year":"1967","unstructured":"Rosman NP, Pearce J. The brain in multiple neurofibromatosis (von Recklinghausen's disease): a suggested neuropathological basis for the associated mental defect. Brain. 1967;90:829\u201338.","journal-title":"Brain"},{"key":"517_CR14","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S0022-3476(89)80137-4","volume":"114","author":"R Listernick","year":"1989","unstructured":"Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with neurofibromatosis type 1. J Pediatr. 1989;114:788\u201392.","journal-title":"J Pediatr"},{"key":"517_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1177\/0883073808316366","volume":"23","author":"LC Krab","year":"2008","unstructured":"Krab LC, Aarsen FK, de Goede-Bolder A, Catsman-Berrevoets CE, Arts WF, Moll HA, Elgersma Y. Impact of neurofibromatosis type 1 on school performance. J Child Neurol. 2008;23:1002\u201310.","journal-title":"J Child Neurol"},{"key":"517_CR16","doi-asserted-by":"publisher","first-page":"13141","DOI":"10.1073\/pnas.1004829107","volume":"107","author":"C Shilyansky","year":"2010","unstructured":"Shilyansky C, Karlsgodt KH, Cummings DM, Sidiropoulou K, Hardt M, James AS, Ehninger D, Bearden CE, Poirazi P, Jentsch JD, et al. Neurofibromin regulates corticostriatal inhibitory networks during working memory performance. Proc Natl Acad Sci U S A. 2010;107:13141\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(01)00245-8","volume":"104","author":"K Cichowski","year":"2001","unstructured":"Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104:593\u2013604.","journal-title":"Cell."},{"key":"517_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1006\/excr.2000.5138","volume":"264","author":"Y Zhu","year":"2001","unstructured":"Zhu Y, Parada LF. Neurofibromin, a tumor suppressor in the nervous system. Exp Cell Res. 2001;264:19\u201328.","journal-title":"Exp Cell Res"},{"key":"517_CR19","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2302\/kjm.2013-0002-RE","volume":"62","author":"H Brems","year":"2013","unstructured":"Brems H, Legius E. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1. Keio J Med. 2013;62:107\u201312.","journal-title":"Keio J Med"},{"key":"517_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1542\/peds.2007-3204","volume":"123","author":"VC Williams","year":"2009","unstructured":"Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics. 2009;123:124\u201333.","journal-title":"Pediatrics."},{"key":"517_CR21","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1086\/340847","volume":"70","author":"M Tartaglia","year":"2002","unstructured":"Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet. 2002;70:1555\u201363.","journal-title":"Am J Hum Genet"},{"key":"517_CR22","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/ng2078","volume":"39","author":"MA Razzaque","year":"2007","unstructured":"Razzaque MA, Nishizawa T, Komoike Y, Yagi H, Furutani M, Amo R, Kamisago M, Momma K, Katayama H, Nakagawa M, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet. 2007;39:1013\u20137.","journal-title":"Nat Genet"},{"key":"517_CR23","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1038\/ng2073","volume":"39","author":"B Pandit","year":"2007","unstructured":"Pandit B, Sarkozy A, Pennacchio LA, Carta C, Oishi K, Martinelli S, Pogna EA, Schackwitz W, Ustaszewska A, Landstrom A, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39:1007\u201312.","journal-title":"Nat Genet"},{"key":"517_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/ng1939","volume":"39","author":"M Tartaglia","year":"2007","unstructured":"Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet. 2007;39:75\u20139.","journal-title":"Nat Genet"},{"key":"517_CR25","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/ng1748","volume":"38","author":"S Schubbert","year":"2006","unstructured":"Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet. 2006;38:331\u20136.","journal-title":"Nat Genet"},{"key":"517_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1086\/504394","volume":"79","author":"C Carta","year":"2006","unstructured":"Carta C, Pantaleoni F, Bocchinfuso G, Stella L, Vasta I, Sarkozy A, Digilio C, Palleschi A, Pizzuti A, Grammatico P, et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet. 2006;79:129\u201335.","journal-title":"Am J Hum Genet"},{"key":"517_CR27","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1136\/jmg.2007.050450","volume":"44","author":"C Nava","year":"2007","unstructured":"Nava C, Hanna N, Michot C, Pereira S, Pouvreau N, Niihori T, Aoki Y, Matsubara Y, Arveiler B, Lacombe D, et al. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS\/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome. J Med Genet. 2007;44:763\u201371.","journal-title":"J Med Genet"},{"key":"517_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/jnnp.45.8.753","volume":"45","author":"A Peiris","year":"1982","unstructured":"Peiris A, Ball MJ. Chiari (type 1) malformation and syringomyelia in a patient with Noonan's syndrome. J Neurol Neurosurg Psychiatry. 1982;45:753\u20134.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"517_CR29","first-page":"101","volume":"40","author":"I Kobayashi","year":"1986","unstructured":"Kobayashi I, Aikawa T, Takemiya T, Maruyama S, Takano K. Noonan\u2019s syndrome with syringomyelia. Jpn J Psychiatry Neurol. 1986;40:101\u20134.","journal-title":"Jpn J Psychiatry Neurol"},{"key":"517_CR30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1055\/s-2008-1035646","volume":"192","author":"W Gorke","year":"1980","unstructured":"Gorke W. Cerebral defects in Noonan's syndrome (author's transl). Klin Padiatr. 1980;192:577\u201381.","journal-title":"Klin Padiatr"},{"key":"517_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/archpedi.1968.02100020377005","volume":"116","author":"JA Noonan","year":"1968","unstructured":"Noonan JA. Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child. 1968;116:373\u201380.","journal-title":"Am J Dis Child"},{"key":"517_CR32","first-page":"177","volume":"33","author":"R Raman Unnithan","year":"1985","unstructured":"Raman Unnithan R, Bahuleyan CG, Matnew Roy VC. Noonan syndrome. J Assoc Physicians India. 1985;33:177\u20139.","journal-title":"J Assoc Physicians India"},{"key":"517_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0887-8994(97)00094-5","volume":"17","author":"Y Saito","year":"1997","unstructured":"Saito Y, Sasaki M, Hanaoka S, Sugai K, Hashimoto T. A case of Noonan syndrome with cortical dysplasia. Pediatr Neurol. 1997;17:266\u20139.","journal-title":"Pediatr Neurol"},{"issue":"2","key":"517_CR34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/ajmg.a.32488","volume":"149A","author":"Laura Cesarini","year":"2009","unstructured":"Cesarini L, Alfieri P, Pantaleoni F, Vasta I, Cerutti M, Petrangeli V, Mariotti P, Leoni C, Ricci D, Vicari S, et al. Cognitive profile of disorders associated with dysregulation of the RAS\/MAPK signaling cascade. Am J Med Genet A. 2009;149A(2):140\u20136.","journal-title":"American Journal of Medical Genetics Part A"},{"key":"517_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1601-183X.2008.00469.x","volume":"8","author":"EI Pierpont","year":"2009","unstructured":"Pierpont EI, Pierpont ME, Mendelsohn NJ, Roberts AE, Tworog-Dube E, Seidenberg MS. Genotype differences in cognitive functioning in Noonan syndrome. Genes Brain Behav. 2009;8:275\u201382.","journal-title":"Genes Brain Behav"},{"key":"517_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajhg.2013.05.021","volume":"93","author":"Y Aoki","year":"2013","unstructured":"Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, Ogata T, Takada F, Yano M, Ando T, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS\/MAPK pathway syndrome. Am J Hum Genet. 2013;93:173\u201380.","journal-title":"Am J Hum Genet"},{"key":"517_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1469-8749.2005.tb01037.x","volume":"47","author":"DA Lee","year":"2005","unstructured":"Lee DA, Portnoy S, Hill P, Gillberg C, Patton MA. Psychological profile of children with Noonan syndrome. Dev Med Child Neurol. 2005;47:35\u20138.","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"517_CR38","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1002\/ajmg.a.34419","volume":"158A","author":"Md. Abdur Razzaque","year":"2012","unstructured":"Razzaque MA, Komoike Y, Nishizawa T, Inai K, Furutani M, Higashinakagawa T, Matsuoka R. Characterization of a novel KRAS mutation identified in Noonan syndrome. Am J Med Genet A. 2012;158A(3):524\u201332.","journal-title":"American Journal of Medical Genetics Part A"},{"key":"517_CR39","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","volume":"381","author":"AE Roberts","year":"2013","unstructured":"Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet. 2013;381:333\u201342.","journal-title":"Lancet"},{"key":"517_CR40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0022-3476(99)70089-2","volume":"135","author":"I van der Burgt","year":"1999","unstructured":"van der Burgt I, Thoonen G, Roosenboom N, Assman-Hulsmans C, Gabreels F, Otten B, Brunner HG. Patterns of cognitive functioning in school-aged children with Noonan syndrome associated with variability in phenotypic expression. J Pediatr. 1999;135:707\u201313.","journal-title":"J Pediatr"},{"key":"517_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/ng1749","volume":"38","author":"T Niihori","year":"2006","unstructured":"Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet. 2006;38:294\u20136.","journal-title":"Nat Genet"},{"key":"517_CR42","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1126\/science.1124642","volume":"311","author":"P Rodriguez-Viciana","year":"2006","unstructured":"Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science. 2006;311:1287\u201390.","journal-title":"Science"},{"key":"517_CR43","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/ajmg.a.31658","volume":"143a","author":"Y Narumi","year":"2007","unstructured":"Narumi Y, Aoki Y, Niihori T, Neri G, Cave H, Verloes A, Nava C, Kavamura MI, Okamoto N, Kurosawa K, et al. Molecular and clinical characterization of cardio-facio-cutaneous (CFC) syndrome: overlapping clinical manifestations with Costello syndrome. Am J Med Genet A. 2007;143a:799\u2013807.","journal-title":"Am J Med Genet A"},{"key":"517_CR44","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1002\/ajmg.1320250303","volume":"25","author":"JF Reynolds","year":"1986","unstructured":"Reynolds JF, Neri G, Herrmann JP, Blumberg B, Coldwell JG, Miles PV, Opitz JM. New multiple congenital anomalies\/mental retardation syndrome with cardio-facio-cutaneous involvement--the CFC syndrome. Am J Med Genet. 1986;25:413\u201327.","journal-title":"Am J Med Genet"},{"key":"517_CR45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/ajmg.1320270404","volume":"27","author":"G Neri","year":"1987","unstructured":"Neri G, Sabatino G, Bertini E, Genuardi M. The CFC syndrome--report of the first two cases outside the United States. Am J Med Genet. 1987;27:767\u201371.","journal-title":"Am J Med Genet"},{"key":"517_CR46","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ajmg.1320330410","volume":"33","author":"K Chrzanowska","year":"1989","unstructured":"Chrzanowska K, Fryns JP, Van den Berghe H. Cardio-facio-cutaneous (CFC) syndrome: report of a new patient. Am J Med Genet. 1989;33:471\u20133.","journal-title":"Am J Med Genet"},{"key":"517_CR47","first-page":"145","volume":"1","author":"LC Ades","year":"1992","unstructured":"Ades LC, Sillence DO, Rogers M. Cardiofaciocutaneous syndrome. Clin Dysmorphol. 1992;1:145\u201350.","journal-title":"Clin Dysmorphol"},{"key":"517_CR48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3928\/0191-3913-19930101-12","volume":"30","author":"TL Young","year":"1993","unstructured":"Young TL, Ziylan S, Schaffer DB. The ophthalmologic manifestations of the cardio-facio-cutaneous syndrome. J Pediatr Ophthalmol Strabismus. 1993;30:48\u201352.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"517_CR49","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00019605-199601000-00010","volume":"5","author":"M Krajewska-Walasek","year":"1996","unstructured":"Krajewska-Walasek M, Chrzanowska K, Jastrzbska M. The cardio-facio-cutaneous (CFC) syndrome--two possible new cases and review of the literature. Clin Dysmorphol. 1996;5:65\u201372.","journal-title":"Clin Dysmorphol"},{"key":"517_CR50","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/j.1469-8749.2007.00894.x","volume":"49","author":"G Yoon","year":"2007","unstructured":"Yoon G, Rosenberg J, Blaser S, Rauen KA. Neurological complications of cardio-facio-cutaneous syndrome. Dev Med Child Neurol. 2007;49:894\u20139.","journal-title":"Dev Med Child Neurol"},{"key":"517_CR51","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajmg.1320440531","volume":"44","author":"M Somer","year":"1992","unstructured":"Somer M, Peippo M, Aalto-Korte K, Ritvanen A, Niemi KM. Cardio-facio-cutaneous syndrome: three additional cases and review of the literature. Am J Med Genet. 1992;44:691\u20135.","journal-title":"Am J Med Genet"},{"key":"517_CR52","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/1096-8628(20001113)95:2<135::AID-AJMG8>3.0.CO;2-J","volume":"95","author":"TA Grebe","year":"2000","unstructured":"Grebe TA, Clericuzio C. Neurologic and gastrointestinal dysfunction in cardio-facio-cutaneous syndrome: identification of a severe phenotype. Am J Med Genet. 2000;95:135\u201343.","journal-title":"Am J Med Genet"},{"key":"517_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.a.30834","volume":"137","author":"EA Manci","year":"2005","unstructured":"Manci EA, Martinez JE, Horenstein MG, Gardner TM, Ahmed A, Mancao MC, Gremse DA, Gardner DM, Nimityongskul P, Maertens P, et al. Cardiofaciocutaneous syndrome (CFC) with congenital peripheral neuropathy and nonorganic malnutrition: an autopsy study. Am J Med Genet A. 2005;137:1\u20138.","journal-title":"Am J Med Genet A"},{"key":"517_CR54","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/jmg.23.2.161","volume":"23","author":"M Baraitser","year":"1986","unstructured":"Baraitser M, Patton MA. A Noonan-like short stature syndrome with sparse hair. J Med Genet. 1986;23:161\u20134.","journal-title":"J Med Genet"},{"key":"517_CR55","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/jmg.2007.054460","volume":"45","author":"CM Armour","year":"2008","unstructured":"Armour CM, Allanson JE. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. J Med Genet. 2008;45:249\u201354.","journal-title":"J Med Genet"},{"key":"517_CR56","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ajmg.a.33787","volume":"155a","author":"E Papadopoulou","year":"2011","unstructured":"Papadopoulou E, Sifakis S, Sol-Church K, Klein-Zighelboim E, Stabley DL, Raissaki M, Gripp KW, Kalmanti M. CNS imaging is a key diagnostic tool in the evaluation of patients with CFC syndrome: two cases and literature review. Am J Med Genet A. 2011;155a:605\u201311.","journal-title":"Am J Med Genet A"},{"key":"517_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1399-0004.1997.tb02512.x","volume":"52","author":"D Wieczorek","year":"1997","unstructured":"Wieczorek D, Majewski F, Gillessen-Kaesbach G. Cardio-facio-cutaneous (CFC) syndrome--a distinct entity? Report of three patients demonstrating the diagnostic difficulties in delineation of CFC syndrome. Clin Genet. 1997;52:37\u201346.","journal-title":"Clin Genet"},{"key":"517_CR58","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1136\/jmg.2006.042796","volume":"43","author":"A Roberts","year":"2006","unstructured":"Roberts A, Allanson J, Jadico SK, Kavamura MI, Noonan J, Opitz JM, Young T, Neri G. The cardiofaciocutaneous syndrome. J Med Genet. 2006;43:833\u201342.","journal-title":"J Med Genet"},{"key":"517_CR59","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1399-0004.2007.00931.x","volume":"73","author":"AL Schulz","year":"2008","unstructured":"Schulz AL, Albrecht B, Arici C, van der Burgt I, Buske A, Gillessen-Kaesbach G, Heller R, Horn D, Hubner CA, Korenke GC, et al. Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet. 2008;73:62\u201370.","journal-title":"Clin Genet"},{"key":"517_CR60","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/ng1641","volume":"37","author":"Y Aoki","year":"2005","unstructured":"Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet. 2005;37:1038\u201340.","journal-title":"Nat Genet"},{"key":"517_CR61","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/jmg.2005.040352","volume":"43","author":"B Kerr","year":"2006","unstructured":"Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden OB, O'Sullivan J, et al. Genotype-phenotype correlation in Costello syndrome: HRAS mutation analysis in 43 cases. J Med Genet. 2006;43:401\u20135.","journal-title":"J Med Genet"},{"key":"517_CR62","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ajmg.a.31078","volume":"140","author":"AL Estep","year":"2006","unstructured":"Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am J Med Genet A. 2006;140:8\u201316.","journal-title":"Am J Med Genet A"},{"key":"517_CR63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/jmg.2006.046300","volume":"44","author":"M Zenker","year":"2007","unstructured":"Zenker M, Lehmann K, Schulz AL, Barth H, Hansmann D, Koenig R, Korinthenberg R, Kreiss-Nachtsheim M, Meinecke P, Morlot S, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet. 2007;44:131\u20135.","journal-title":"J Med Genet"},{"key":"517_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajmg.1320410118","volume":"41","author":"VM Der Kaloustian","year":"1991","unstructured":"Der Kaloustian VM, Moroz B, McIntosh N, Watters AK, Blaichman S. Costello syndrome. Am J Med Genet. 1991;41:69\u201373.","journal-title":"Am J Med Genet"},{"key":"517_CR65","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/ajmg.1320470210","volume":"47","author":"G Zampino","year":"1993","unstructured":"Zampino G, Mastroiacovo P, Ricci R, Zollino M, Segni G, Martini-Neri ME, Neri G. Costello syndrome: further clinical delineation, natural history, genetic definition, and nosology. Am J Med Genet. 1993;47:176\u201383.","journal-title":"Am J Med Genet"},{"key":"517_CR66","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/(SICI)1096-8628(20000131)90:3<256::AID-AJMG16>3.0.CO;2-D","volume":"90","author":"KW Gripp","year":"2000","unstructured":"Gripp KW, Scott CI Jr, Nicholson L, Figueroa TE. Second case of bladder carcinoma in a patient with Costello syndrome. Am J Med Genet. 2000;90:256\u20139.","journal-title":"Am J Med Genet"},{"key":"517_CR67","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ajmg.10241","volume":"108","author":"KW Gripp","year":"2002","unstructured":"Gripp KW, Scott CI Jr, Nicholson L, McDonald-McGinn DM, Ozeran JD, Jones MC, Lin AE, Zackai EH. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet. 2002;108:80\u20137.","journal-title":"Am J Med Genet"},{"key":"517_CR68","first-page":"337","volume":"5","author":"JP Fryns","year":"1994","unstructured":"Fryns JP, Vogels A, Haegeman J, Eggermont E, van den Berghe H. Costello syndrome: a postnatal growth retardation syndrome with distinct phenotype. Genet Couns. 1994;5:337\u201343.","journal-title":"Genet Couns"},{"key":"517_CR69","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S0022-3476(98)70284-7","volume":"133","author":"JP Johnson","year":"1998","unstructured":"Johnson JP, Golabi M, Norton ME, Rosenblatt RM, Feldman GM, Yang SP, Hall BD, Fries MH, Carey JC. Costello syndrome: phenotype, natural history, differential diagnosis, and possible cause. J Pediatr. 1998;133:441\u20138.","journal-title":"J Pediatr"},{"key":"517_CR70","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jmg.35.12.1036","volume":"35","author":"B Kerr","year":"1998","unstructured":"Kerr B, Eden OB, Dandamudi R, Shannon N, Quarrell O, Emmerson A, Ladusans E, Gerrard M, Donnai D. Costello syndrome: two cases with embryonal rhabdomyosarcoma. J Med Genet. 1998;35:1036\u20139.","journal-title":"J Med Genet"},{"key":"517_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/(SICI)1096-8628(19990115)82:2<187::AID-AJMG17>3.0.CO;2-2","volume":"82","author":"AM van Eeghen","year":"1999","unstructured":"van Eeghen AM, van Gelderen I, Hennekam RC. Costello syndrome: report and review. Am J Med Genet. 1999;82:187\u201393.","journal-title":"Am J Med Genet"},{"key":"517_CR72","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/ajmg.1320470203","volume":"47","author":"B Say","year":"1993","unstructured":"Say B, Gucsavas M, Morgan H, York C. The Costello syndrome. Am J Med Genet. 1993;47:163\u20135.","journal-title":"Am J Med Genet"},{"key":"517_CR73","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ajmg.a.20330","volume":"123a","author":"MA Delrue","year":"2003","unstructured":"Delrue MA, Chateil JF, Arveiler B, Lacombe D. Costello syndrome and neurological abnormalities. Am J Med Genet. 2003;123a:301\u20135.","journal-title":"Am J Med Genet"},{"key":"517_CR74","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/BF00202834","volume":"93","author":"N Okamoto","year":"1994","unstructured":"Okamoto N, Chiyo H, Imai K, Otani K, Futagi Y. A Japanese patient with the Costello syndrome. Hum Genet. 1994;93:605\u20136.","journal-title":"Hum Genet"},{"key":"517_CR75","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1006\/dbio.1999.9327","volume":"212","author":"MM Lakkis","year":"1999","unstructured":"Lakkis MM, Golden JA, O'Shea KS, Epstein JA. Neurofibromin deficiency in mice causes exencephaly and is a modifier for Splotch neural tube defects. Dev Biol. 1999;212:80\u201392.","journal-title":"Dev Biol"},{"key":"517_CR76","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1101\/gad.8.9.1019","volume":"8","author":"CI Brannan","year":"1994","unstructured":"Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994;8:1019\u201329.","journal-title":"Genes Dev"},{"key":"517_CR77","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/ng0794-353","volume":"7","author":"T Jacks","year":"1994","unstructured":"Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet. 1994;7:353\u201361.","journal-title":"Nat Genet"},{"key":"517_CR78","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1038\/sj.onc.1202829","volume":"18","author":"DH Gutmann","year":"1999","unstructured":"Gutmann DH, Loehr A, Zhang Y, Kim J, Henkemeyer M, Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene. 1999;18:4450\u20139.","journal-title":"Oncogene."},{"key":"517_CR79","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0006-8993(98)01133-0","volume":"816","author":"TA Rizvi","year":"1999","unstructured":"Rizvi TA, Akunuru S, de Courten-Myers G, Switzer RC 3rd, Nordlund ML, Ratner N. Region-specific astrogliosis in brains of mice heterozygous for mutations in the neurofibromatosis type 1 (Nf1) tumor suppressor. Brain Res. 1999;816:111\u201323.","journal-title":"Brain Res"},{"key":"517_CR80","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature711","volume":"415","author":"RM Costa","year":"2002","unstructured":"Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 2002;415:526\u201330.","journal-title":"Nature."},{"key":"517_CR81","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/ng0397-281","volume":"15","author":"AJ Silva","year":"1997","unstructured":"Silva AJ, Frankland PW, Marowitz Z, Friedman E, Laszlo GS, Cioffi D, Jacks T, Bourtchuladze R. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet. 1997;15:281\u20134.","journal-title":"Nat Genet"},{"key":"517_CR82","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/86898","volume":"27","author":"RM Costa","year":"2001","unstructured":"Costa RM, Yang T, Huynh DP, Pulst SM, Viskochil DH, Silva AJ, Brannan CI. Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1. Nat Genet. 2001;27:399\u2013405.","journal-title":"Nat Genet"},{"key":"517_CR83","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1101\/gad.862101","volume":"15","author":"Y Zhu","year":"2001","unstructured":"Zhu Y, Romero MI, Ghosh P, Ye Z, Charnay P, Rushing EJ, Marth JD, Parada LF. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes Dev. 2001;15:859\u201376.","journal-title":"Genes Dev"},{"key":"517_CR84","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2008.09.060","volume":"135","author":"Y Cui","year":"2008","unstructured":"Cui Y, Costa RM, Murphy GG, Elgersma Y, Zhu Y, Gutmann DH, Parada LF, Mody I, Silva AJ. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell. 2008;135:549\u201360.","journal-title":"Cell."},{"key":"517_CR85","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.cell.2012.06.034","volume":"150","author":"Y Wang","year":"2012","unstructured":"Wang Y, Kim E, Wang X, Novitch BG, Yoshikawa K, Chang LS, Zhu Y. ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities. Cell. 2012;150:816\u201330.","journal-title":"Cell."},{"key":"517_CR86","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.1242\/dev.02162","volume":"132","author":"Y Zhu","year":"2005","unstructured":"Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, Burns DK, Bajenaru ML, Gutmann DH, Parada LF. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development. 2005;132:5577\u201388.","journal-title":"Development"},{"key":"517_CR87","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1523\/JNEUROSCI.5236-07.2008","volume":"28","author":"ME Lush","year":"2008","unstructured":"Lush ME, Li Y, Kwon CH, Chen J, Parada LF. Neurofibromin is required for barrel formation in the mouse somatosensory cortex. J Neurosci. 2008;28:1580\u20137.","journal-title":"J Neurosci"},{"key":"517_CR88","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1101\/gad.246603.114","volume":"28","author":"E Sanchez-Ortiz","year":"2014","unstructured":"Sanchez-Ortiz E, Cho W, Nazarenko I, Mo W, Chen J, Parada LF. NF1 regulation of RAS\/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development. Genes Dev. 2014;28:2407\u201320.","journal-title":"Genes Dev"},{"key":"517_CR89","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.stem.2007.07.008","volume":"1","author":"B Hegedus","year":"2007","unstructured":"Hegedus B, Dasgupta B, Shin JE, Emnett RJ, Hart-Mahon EK, Elghazi L, Bernal-Mizrachi E, Gutmann DH. Neurofibromatosis-1 regulates neuronal and glial cell differentiation from neuroglial progenitors in vivo by both cAMP- and Ras-dependent mechanisms. Cell Stem Cell. 2007;1:443\u201357.","journal-title":"Cell Stem Cell"},{"key":"517_CR90","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1038\/nn.4159","volume":"18","author":"GJ Sun","year":"2015","unstructured":"Sun GJ, Zhou Y, Ito S, Bonaguidi MA, Stein-O'Brien G, Kawasaki NK, Modak N, Zhu Y, Ming GL, Song H. Latent tri-lineage potential of adult hippocampal neural stem cells revealed by Nf1 inactivation. Nat Neurosci. 2015;18:1722\u20134.","journal-title":"Nat Neurosci"},{"key":"517_CR91","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1523\/JNEUROSCI.3469-11.2012","volume":"32","author":"Y Li","year":"2012","unstructured":"Li Y, Li Y, McKay RM, Riethmacher D, Parada LF. Neurofibromin modulates adult hippocampal neurogenesis and behavioral effects of antidepressants. J Neurosci. 2012;32:3529\u201339.","journal-title":"J Neurosci"},{"key":"517_CR92","doi-asserted-by":"publisher","first-page":"6706","DOI":"10.1128\/MCB.01225-07","volume":"27","author":"Y Ke","year":"2007","unstructured":"Ke Y, Zhang EE, Hagihara K, Wu D, Pang Y, Klein R, Curran T, Ranscht B, Feng GS. Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol Cell Biol. 2007;27:6706\u201317.","journal-title":"Mol Cell Biol"},{"key":"517_CR93","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/glia.21016","volume":"58","author":"Y Zhu","year":"2010","unstructured":"Zhu Y, Park J, Hu X, Zheng K, Li H, Cao Q, Feng GS, Qiu M. Control of oligodendrocyte generation and proliferation by Shp2 protein tyrosine phosphatase. Glia. 2010;58:1407\u201314.","journal-title":"Glia."},{"key":"517_CR94","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1523\/JNEUROSCI.3515-13.2014","volume":"34","author":"LA Ehrman","year":"2014","unstructured":"Ehrman LA, Nardini D, Ehrman S, Rizvi TA, Gulick J, Krenz M, Dasgupta B, Robbins J, Ratner N, Nakafuku M, et al. The protein tyrosine phosphatase Shp2 is required for the generation of oligodendrocyte progenitor cells and myelination in the mouse telencephalon. J Neurosci. 2014;34:3767\u201378.","journal-title":"J Neurosci"},{"issue":"522","key":"517_CR95","doi-asserted-by":"publisher","first-page":"eaao1591","DOI":"10.1126\/scisignal.aao1591","volume":"11","author":"Hong Zheng","year":"2018","unstructured":"Zheng H, Yu WM, Waclaw RR, Kontaridis MI, Neel BG, Qu CK. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner. Sci Signal. 2018;11:eaao1591.","journal-title":"Science Signaling"},{"key":"517_CR96","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.neuron.2007.03.027","volume":"54","author":"AS Gauthier","year":"2007","unstructured":"Gauthier AS, Furstoss O, Araki T, Chan R, Neel BG, Kaplan DR, Miller FD. Control of CNS cell-fate decisions by SHP-2 and its dysregulation in Noonan syndrome. Neuron. 2007;54:245\u201362.","journal-title":"Neuron."},{"key":"517_CR97","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/nn.3863","volume":"17","author":"YS Lee","year":"2014","unstructured":"Lee YS, Ehninger D, Zhou M, Oh JY, Kang M, Kwak C, Ryu HH, Butz D, Araki T, Cai Y, et al. Mechanism and treatment for learning and memory deficits in mouse models of Noonan syndrome. Nat Neurosci. 2014;17:1736\u201343.","journal-title":"Nat Neurosci"},{"key":"517_CR98","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nm1084","volume":"10","author":"T Araki","year":"2004","unstructured":"Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL, Yang W, Pao LI, Gilliland DG, Epstein JA, et al. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med. 2004;10:849\u201357.","journal-title":"Nat Med"},{"issue":"3","key":"517_CR99","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.biopsych.2016.06.016","volume":"81","author":"Alessandro Papale","year":"2017","unstructured":"Papale A, d'Isa R, Menna E, Cerovic M, Solari N, Hardingham N, Cambiaghi M, Cursi M, Barbacid M, Leocani L, et al. Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies. Biol Psychiatry. 2017;81:179\u201392.","journal-title":"Biological Psychiatry"},{"key":"517_CR100","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/s41598-017-01218-0","volume":"7","author":"J Schreiber","year":"2017","unstructured":"Schreiber J, Grimbergen LA, Overwater I, Vaart TV, Stedehouder J, Schuhmacher AJ, Guerra C, Kushner SA, Jaarsma D, Elgersma Y. Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models. Sci Rep. 2017;7:1256.","journal-title":"Sci Rep"},{"key":"517_CR101","doi-asserted-by":"publisher","first-page":"9721","DOI":"10.1523\/JNEUROSCI.2836-05.2005","volume":"25","author":"SA Kushner","year":"2005","unstructured":"Kushner SA, Elgersma Y, Murphy GG, Jaarsma D, van Woerden GM, Hojjati MR, Cui Y, LeBoutillier JC, Marrone DF, Choi ES, et al. Modulation of presynaptic plasticity and learning by the H-ras\/extracellular signal-regulated kinase\/synapsin I signaling pathway. J Neurosci. 2005;25:9721\u201334.","journal-title":"J Neurosci"},{"key":"517_CR102","doi-asserted-by":"publisher","first-page":"e58259","DOI":"10.1371\/journal.pone.0058259","volume":"8","author":"V Pfeiffer","year":"2013","unstructured":"Pfeiffer V, Gotz R, Xiang C, Camarero G, Braun A, Zhang Y, Blum R, Heinsen H, Nieswandt B, Rapp UR. Ablation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellum. PLoS One. 2013;8:e58259.","journal-title":"PLoS One"},{"key":"517_CR103","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1083\/jcb.200709069","volume":"180","author":"G Galabova-Kovacs","year":"2008","unstructured":"Galabova-Kovacs G, Catalanotti F, Matzen D, Reyes GX, Zezula J, Herbst R, Silva A, Walter I, Baccarini M. Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development. J Cell Biol. 2008;180:947\u201355.","journal-title":"J Cell Biol"},{"key":"517_CR104","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1073\/pnas.1016933108","volume":"108","author":"J Urosevic","year":"2011","unstructured":"Urosevic J, Sauzeau V, Soto-Montenegro ML, Reig S, Desco M, Wright EM, Canamero M, Mulero F, Ortega S, Bustelo XR, et al. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc Natl Acad Sci U S A. 2011;108:5015\u201320.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR105","doi-asserted-by":"publisher","first-page":"e0192067","DOI":"10.1371\/journal.pone.0192067","volume":"13","author":"V Pfeiffer","year":"2018","unstructured":"Pfeiffer V, Gotz R, Camarero G, Heinsen H, Blum R, Rapp UR. Impaired neuronal maturation of hippocampal neural progenitor cells in mice lacking CRAF. PLoS One. 2018;13:e0192067.","journal-title":"PLoS One"},{"key":"517_CR106","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S0959-437X(99)00005-2","volume":"9","author":"T Preiss","year":"1999","unstructured":"Preiss T, Hentze MW. From factors to mechanisms: translation and translational control in eukaryotes. Curr Opin Genet Dev. 1999;9:515\u201321.","journal-title":"Curr Opin Genet Dev"},{"key":"517_CR107","doi-asserted-by":"publisher","first-page":"e1008108","DOI":"10.1371\/journal.pgen.1008108","volume":"15","author":"MC Holter","year":"2019","unstructured":"Holter MC, Hewitt LT, Koebele SV, Judd JM, Xing L, Bimonte-Nelson HA, Conrad CD, Araki T, Neel BG, Snider WD, et al. The Noonan Syndrome-linked Raf1L613V mutation drives increased glial number in the mouse cortex and enhanced learning. PLoS Genet. 2019;15:e1008108.","journal-title":"PLoS Genet"},{"issue":"3","key":"517_CR108","doi-asserted-by":"publisher","first-page":"dmm031278","DOI":"10.1242\/dmm.031278","volume":"11","author":"Rifdat Aoidi","year":"2018","unstructured":"Aoidi R, Houde N, Landry-Truchon K, Holter M, Jacquet K, Charron L, Krishnaswami SR, Yu BD, Rauen KA, Bisson N, et al. Mek1(Y130C) mice recapitulate aspects of human cardio-facio-cutaneous syndrome. Dis Model Mech. 2018;11:dmm031278.","journal-title":"Disease Models & Mechanisms"},{"key":"517_CR109","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.neuron.2012.08.031","volume":"75","author":"X Li","year":"2012","unstructured":"Li X, Newbern JM, Wu Y, Morgan-Smith M, Zhong J, Charron J, Snider WD. MEK Is a Key Regulator of Gliogenesis in the Developing Brain. Neuron. 2012;75:1035\u201350.","journal-title":"Neuron."},{"key":"517_CR110","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0006-8993(00)03149-8","volume":"889","author":"T Ivanova","year":"2001","unstructured":"Ivanova T, Karolczak M, Beyer C. Estrogen stimulates the mitogen-activated protein kinase pathway in midbrain astroglia. Brain Res. 2001;889:264\u20139.","journal-title":"Brain Res"},{"key":"517_CR111","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1242\/dev.01199","volume":"131","author":"LS Campos","year":"2004","unstructured":"Campos LS, Leone DP, Relvas JB, Brakebusch C, Fassler R, Suter U. ffrench-Constant C. Beta1 integrins activate a MAPK signalling pathway in neural stem cells that contributes to their maintenance. Development. 2004;131:3433\u201344.","journal-title":"Development"},{"key":"517_CR112","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.286.5443.1358","volume":"286","author":"A Bonni","year":"1999","unstructured":"Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286:1358\u201362.","journal-title":"Science"},{"key":"517_CR113","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1126\/science.270.5240.1326","volume":"270","author":"Z Xia","year":"1995","unstructured":"Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science. 1995;270:1326\u201331.","journal-title":"Science."},{"key":"517_CR114","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0896-6273(00)80282-2","volume":"17","author":"TM Michaelidis","year":"1996","unstructured":"Michaelidis TM, Sendtner M, Cooper JD, Airaksinen MS, Holtmann B, Meyer M, Thoenen H. Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron. 1996;17:75\u201389.","journal-title":"Neuron."},{"key":"517_CR115","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1038\/sj.onc.1206598","volume":"22","author":"M Krasilnikov","year":"2003","unstructured":"Krasilnikov M, Ivanov VN, Dong J, Ronai Z. ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis. Oncogene. 2003;22:4092\u2013101.","journal-title":"Oncogene."},{"key":"517_CR116","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1046\/j.1471-4159.2001.00304.x","volume":"77","author":"SM Kulich","year":"2001","unstructured":"Kulich SM, Chu CT. Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: implications for Parkinson's disease. J Neurochem. 2001;77:1058\u201366.","journal-title":"J Neurochem"},{"key":"517_CR117","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1749-6632.2002.tb04660.x","volume":"973","author":"C Russo","year":"2002","unstructured":"Russo C, Dolcini V, Salis S, Venezia V, Violani E, Carlo P, Zambrano N, Russo T, Schettini G. Signal transduction through tyrosine-phosphorylated carboxy-terminal fragments of APP via an enhanced interaction with Shc\/Grb2 adaptor proteins in reactive astrocytes of Alzheimer's disease brain. Ann N Y Acad Sci. 2002;973:323\u201333.","journal-title":"Ann N Y Acad Sci"},{"key":"517_CR118","doi-asserted-by":"publisher","first-page":"8663","DOI":"10.1523\/JNEUROSCI.1107-12.2012","volume":"32","author":"J Pucilowska","year":"2012","unstructured":"Pucilowska J, Puzerey PA, Karlo JC, Galan RF, Landreth GE. Disrupted ERK signaling during cortical development leads to abnormal progenitor proliferation, neuronal and network excitability and behavior, modeling human neuro-cardio-facial-cutaneous and related syndromes. J Neurosci. 2012;32:8663\u201377.","journal-title":"J Neurosci"},{"key":"517_CR119","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0896-6273(02)01026-7","volume":"36","author":"C Menard","year":"2002","unstructured":"Menard C, Hein P, Paquin A, Savelson A, Yang XM, Lederfein D, Barnabe-Heider F, Mir AA, Sterneck E, Peterson AC, et al. An essential role for a MEK-C\/EBP pathway during growth factor-regulated cortical neurogenesis. Neuron. 2002;36:597\u2013610.","journal-title":"Neuron."},{"key":"517_CR120","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nn1192","volume":"7","author":"MR Song","year":"2004","unstructured":"Song MR, Ghosh A. FGF2-induced chromatin remodeling regulates CNTF-mediated gene expression and astrocyte differentiation. Nat Neurosci. 2004;7:229\u201335.","journal-title":"Nat Neurosci"},{"key":"517_CR121","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1242\/dev.128.18.3585","volume":"128","author":"T Morrow","year":"2001","unstructured":"Morrow T, Song MR, Ghosh A. Sequential specification of neurons and glia by developmentally regulated extracellular factors. Development. 2001;128:3585\u201394.","journal-title":"Development"},{"key":"517_CR122","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1046\/j.1471-4159.2001.00350.x","volume":"77","author":"A Bajetto","year":"2001","unstructured":"Bajetto A, Barbero S, Bonavia R, Piccioli P, Pirani P, Florio T, Schettini G. Stromal cell-derived factor-1alpha induces astrocyte proliferation through the activation of extracellular signal-regulated kinases 1\/2 pathway. J Neurochem. 2001;77:1226\u201336.","journal-title":"J Neurochem"},{"key":"517_CR123","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1006\/mcne.1999.0827","volume":"15","author":"W Baron","year":"2000","unstructured":"Baron W, Metz B, Bansal R, Hoekstra D, de Vries H. PDGF and FGF-2 signaling in oligodendrocyte progenitor cells: regulation of proliferation and differentiation by multiple intracellular signaling pathways. Mol Cell Neurosci. 2000;15:314\u201329.","journal-title":"Mol Cell Neurosci"},{"key":"517_CR124","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/glia.22281","volume":"60","author":"HM Guardiola-Diaz","year":"2012","unstructured":"Guardiola-Diaz HM, Ishii A, Bansal R. Erk1\/2 MAPK and mTOR signaling sequentially regulates progression through distinct stages of oligodendrocyte differentiation. Glia. 2012;60:476\u201386.","journal-title":"Glia."},{"key":"517_CR125","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1523\/JNEUROSCI.3239-10.2011","volume":"31","author":"SL Fyffe-Maricich","year":"2011","unstructured":"Fyffe-Maricich SL, Karlo JC, Landreth GE, Miller RH. The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. J Neurosci. 2011;31:843\u201350.","journal-title":"J Neurosci"},{"key":"517_CR126","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/j.1471-4159.2012.07871.x","volume":"122","author":"J Xiao","year":"2012","unstructured":"Xiao J, Ferner AH, Wong AW, Denham M, Kilpatrick TJ, Murray SS. Extracellular signal-regulated kinase 1\/2 signaling promotes oligodendrocyte myelination in vitro. J Neurochem. 2012;122:1167\u201380.","journal-title":"J Neurochem"},{"key":"517_CR127","volume-title":"Gu H, Xie X","author":"N Suo","year":"2019","unstructured":"Suo N, Guo YE, He B. Gu H, Xie X. Glia: Inhibition of MAPK\/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases; 2019."},{"key":"517_CR128","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jnr.490400302","volume":"40","author":"C Fressinaud","year":"1995","unstructured":"Fressinaud C, Vallat JM, Labourdette G. Basic fibroblast growth factor down-regulates myelin basic protein gene expression and alters myelin compaction of mature oligodendrocytes in vitro. J Neurosci Res. 1995;40:285\u201393.","journal-title":"J Neurosci Res"},{"key":"517_CR129","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/(SICI)1097-4547(19971015)50:2<215::AID-JNR10>3.0.CO;2-7","volume":"50","author":"R Bansal","year":"1997","unstructured":"Bansal R, Pfeiffer SE. FGF-2 converts mature oligodendrocytes to a novel phenotype. J Neurosci Res. 1997;50:215\u201328.","journal-title":"J Neurosci Res"},{"key":"517_CR130","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1006\/mcne.1998.0733","volume":"13","author":"PD Canoll","year":"1999","unstructured":"Canoll PD, Kraemer R, Teng KK, Marchionni MA, Salzer JL. GGF\/neuregulin induces a phenotypic reversion of oligodendrocytes. Mol Cell Neurosci. 1999;13:79\u201394.","journal-title":"Mol Cell Neurosci"},{"key":"517_CR131","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1242\/dev.126.3.525","volume":"126","author":"S Casarosa","year":"1999","unstructured":"Casarosa S, Fode C, Guillemot F. Mash1 regulates neurogenesis in the ventral telencephalon. Development. 1999;126:525\u201334.","journal-title":"Development"},{"issue":"suppl_1","key":"517_CR132","doi-asserted-by":"publisher","first-page":"i138","DOI":"10.1093\/cercor\/bhj168","volume":"16","author":"Olivier Britz","year":"2006","unstructured":"Britz O, Mattar P, Nguyen L, Langevin LM, Zimmer C, Alam S, Guillemot F, Schuurmans C. A role for proneural genes in the maturation of cortical progenitor cells. Cereb Cortex. 2006;16:i138\u201351.","journal-title":"Cerebral Cortex"},{"key":"517_CR133","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1523\/JNEUROSCI.0126-07.2007","volume":"27","author":"CM Parras","year":"2007","unstructured":"Parras CM, Hunt C, Sugimori M, Nakafuku M, Rowitch D, Guillemot F. The proneural gene Mash1 specifies an early population of telencephalic oligodendrocytes. J Neurosci. 2007;27:4233\u201342.","journal-title":"J Neurosci"},{"key":"517_CR134","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1523\/JNEUROSCI.4077-13.2014","volume":"34","author":"S Li","year":"2014","unstructured":"Li S, Mattar P, Dixit R, Lawn SO, Wilkinson G, Kinch C, Eisenstat D, Kurrasch DM, Chan JA, Schuurmans C. RAS\/ERK signaling controls proneural genetic programs in cortical development and gliomagenesis. J Neurosci. 2014;34:2169\u201390.","journal-title":"J Neurosci"},{"key":"517_CR135","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nrc839","volume":"2","author":"I Vivanco","year":"2002","unstructured":"Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489\u2013501.","journal-title":"Nat Rev Cancer"},{"key":"517_CR136","first-page":"143","volume":"346","author":"E Castellano","year":"2010","unstructured":"Castellano E, Downward J. Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol. 2010;346:143\u201369.","journal-title":"Curr Top Microbiol Immunol"},{"key":"517_CR137","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3:11\u201322.","journal-title":"Nat Rev Cancer"},{"key":"517_CR138","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36:320\u20138.","journal-title":"Trends Biochem Sci"},{"key":"517_CR139","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/nn.2937","volume":"14","author":"JI Kim","year":"2011","unstructured":"Kim JI, Lee HR, Sim SE, Baek J, Yu NK, Choi JH, Ko HG, Lee YS, Park SW, Kwak C, et al. PI3Kgamma is required for NMDA receptor-dependent long-term depression and behavioral flexibility. Nat Neurosci. 2011;14:1447\u201354.","journal-title":"Nat Neurosci"},{"key":"517_CR140","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13041-014-0078-6","volume":"7","author":"JH Choi","year":"2014","unstructured":"Choi JH, Park P, Baek GC, Sim SE, Kang SJ, Lee Y, Ahn SH, Lim CS, Lee YS, Collingridge GL, et al. Effects of PI3Kgamma overexpression in the hippocampus on synaptic plasticity and spatial learning. Mol Brain. 2014;7:78.","journal-title":"Mol Brain"},{"key":"517_CR141","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1242\/jcs.00963","volume":"117","author":"JS Rawlings","year":"2004","unstructured":"Rawlings JS, Rosler KM, Harrison DA. The JAK\/STAT signaling pathway. J Cell Sci. 2004;117:1281\u20133.","journal-title":"J Cell Sci"},{"key":"517_CR142","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.neuron.2011.11.024","volume":"73","author":"CS Nicolas","year":"2012","unstructured":"Nicolas CS, Peineau S, Amici M, Csaba Z, Fafouri A, Javalet C, Collett VJ, Hildebrandt L, Seaton G, Choi SL, et al. The Jak\/STAT pathway is involved in synaptic plasticity. Neuron. 2012;73:374\u201390.","journal-title":"Neuron."},{"key":"517_CR143","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.tig.2008.07.005","volume":"24","author":"LC Krab","year":"2008","unstructured":"Krab LC, Goorden SM, Elgersma Y. Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases. Trends Genet. 2008;24:498\u2013510.","journal-title":"Trends Genet"},{"key":"517_CR144","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nm0306-283","volume":"12","author":"M Bentires-Alj","year":"2006","unstructured":"Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med. 2006;12:283\u20135.","journal-title":"Nat Med"},{"key":"517_CR145","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0092-8674(90)90253-B","volume":"62","author":"RM Cawthon","year":"1990","unstructured":"Cawthon RM, Weiss R, Xu GF, Viskochil D, Culver M, Stevens J, Robertson M, Dunn D, Gesteland R, O'Connell P, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 1990;62:193\u2013201.","journal-title":"Cell."},{"key":"517_CR146","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","volume":"63","author":"GA Martin","year":"1990","unstructured":"Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O'Connell P, Cawthon RM, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990;63:843\u20139.","journal-title":"Cell."},{"key":"517_CR147","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","volume":"278","author":"DH Gutmann","year":"1997","unstructured":"Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE, Rubenstein A, Viskochil D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. Jama. 1997;278:51\u20137.","journal-title":"Jama."},{"key":"517_CR148","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<38::AID-AJMG8>3.0.CO;2-M","volume":"89","author":"R Listernick","year":"1999","unstructured":"Listernick R, Charrow J, Gutmann DH. Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet. 1999;89:38\u201344.","journal-title":"Am J Med Genet"},{"key":"517_CR149","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/00005072-199507000-00013","volume":"54","author":"ML Nordlund","year":"1995","unstructured":"Nordlund ML, Rizvi TA, Brannan CI, Ratner N. Neurofibromin expression and astrogliosis in neurofibromatosis (type 1) brains. J Neuropathol Exp Neurol. 1995;54:588\u2013600.","journal-title":"J Neuropathol Exp Neurol"},{"key":"517_CR150","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1212\/WNL.54.4.914","volume":"54","author":"BD Moore 3rd","year":"2000","unstructured":"Moore BD 3rd, Slopis JM, Jackson EF, De Winter AE, Leeds NE. Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status. Neurology. 2000;54:914\u201320.","journal-title":"Neurology."},{"key":"517_CR151","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1177\/0883073809350723","volume":"25","author":"N Pride","year":"2010","unstructured":"Pride N, Payne JM, Webster R, Shores EA, Rae C, North KN. Corpus callosum morphology and its relationship to cognitive function in neurofibromatosis type 1. J Child Neurol. 2010;25:834\u201341.","journal-title":"J Child Neurol"},{"key":"517_CR152","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1177\/088307380201700813","volume":"17","author":"RM Costa","year":"2002","unstructured":"Costa RM, Silva AJ. Molecular and cellular mechanisms underlying the cognitive deficits associated with neurofibromatosis 1. J Child Neurol. 2002;17:622\u20136 discussion 7-9, 46-51.","journal-title":"J Child Neurol"},{"key":"517_CR153","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1016\/j.cub.2005.09.043","volume":"15","author":"W Li","year":"2005","unstructured":"Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol. 2005;15:1961\u20137.","journal-title":"Curr Biol"},{"key":"517_CR154","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1474-4422(13)70179-0","volume":"12","author":"MT Acosta","year":"2013","unstructured":"Acosta MT. Challenges of cognitive research in neurofibromatosis type 1. Lancet Neurol. 2013;12:1040\u20131.","journal-title":"Lancet Neurol"},{"key":"517_CR155","doi-asserted-by":"publisher","first-page":"10541","DOI":"10.1523\/JNEUROSCI.18-24-10541.1998","volume":"18","author":"AG Rabchevsky","year":"1998","unstructured":"Rabchevsky AG, Weinitz JM, Coulpier M, Fages C, Tinel M, Junier MP. A role for transforming growth factor alpha as an inducer of astrogliosis. J Neurosci. 1998;18:10541\u201352.","journal-title":"J Neurosci"},{"key":"517_CR156","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/gene.10008","volume":"31","author":"L Zhuo","year":"2001","unstructured":"Zhuo L, Theis M, Alvarez-Maya I, Brenner M, Willecke K, Messing A. hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis. 2001;31:85\u201394.","journal-title":"Genesis"},{"key":"517_CR157","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.1523\/JNEUROSCI.23-18-07207.2003","volume":"23","author":"MR Bennett","year":"2003","unstructured":"Bennett MR, Rizvi TA, Karyala S, McKinnon RD, Ratner N. Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants. J Neurosci. 2003;23:7207\u201317.","journal-title":"J Neurosci"},{"key":"517_CR158","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1128\/MCB.17.2.862","volume":"17","author":"HA Kim","year":"1997","unstructured":"Kim HA, Ling B, Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol Cell Biol. 1997;17:862\u201372.","journal-title":"Mol Cell Biol"},{"key":"517_CR159","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1523\/JNEUROSCI.4693-04.2005","volume":"25","author":"B Dasgupta","year":"2005","unstructured":"Dasgupta B, Gutmann DH. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J Neurosci. 2005;25:5584\u201394.","journal-title":"J Neurosci"},{"key":"517_CR160","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1101\/gad.1957110","volume":"24","author":"DY Lee","year":"2010","unstructured":"Lee DY, Yeh TH, Emnett RJ, White CR, Gutmann DH. Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner. Genes Dev. 2010;24:2317\u201329.","journal-title":"Genes Dev"},{"key":"517_CR161","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0092-8674(02)00677-3","volume":"109","author":"Q Zhou","year":"2002","unstructured":"Zhou Q, Anderson DJ. The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification. Cell. 2002;109:61\u201373.","journal-title":"Cell."},{"issue":"571","key":"517_CR162","doi-asserted-by":"publisher","first-page":"eaau5755","DOI":"10.1126\/scisignal.aau5755","volume":"12","author":"Hyun-Hee Ryu","year":"2019","unstructured":"Ryu HH, Kim T, Kim JW, Kang M, Park P, Kim YG, Kim H, Ha J, Choi JE, Lee J, et al. Excitatory neuron-specific SHP2-ERK signaling network regulates synaptic plasticity and memory. Sci Signal. 2019;12:eaau5755.","journal-title":"Science Signaling"},{"key":"517_CR163","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13041-019-0481-0","volume":"12","author":"HH Ryu","year":"2019","unstructured":"Ryu HH, Kang M, Park J, Park SH, Lee YS. Enriched expression of NF1 in inhibitory neurons in both mouse and human brain. Mol Brain. 2019;12:60.","journal-title":"Mol Brain"},{"key":"517_CR164","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev.genom.6.080604.162305","volume":"6","author":"M Tartaglia","year":"2005","unstructured":"Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet. 2005;6:45\u201368.","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"517_CR165","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1542\/peds.2009-3207","volume":"126","author":"AA Romano","year":"2010","unstructured":"Romano AA, Allanson JE, Dahlgren J, Gelb BD, Hall B, Pierpont ME, Roberts AE, Robinson W, Takemoto CM, Noonan JA. Noonan syndrome: clinical features, diagnosis, and management guidelines. Pediatrics. 2010;126:746\u201359.","journal-title":"Pediatrics."},{"key":"517_CR166","doi-asserted-by":"publisher","first-page":"11473","DOI":"10.1073\/pnas.1324128111","volume":"111","author":"PC Chen","year":"2014","unstructured":"Chen PC, Yin J, Yu HW, Yuan T, Fernandez M, Yung CK, Trinh QM, Peltekova VD, Reid JG, Tworog-Dube E, et al. Next-generation sequencing identifies rare variants associated with Noonan syndrome. Proc Natl Acad Sci U S A. 2014;111:11473\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR167","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ng772","volume":"29","author":"M Tartaglia","year":"2001","unstructured":"Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet. 2001;29:465\u20138.","journal-title":"Nat Genet"},{"key":"517_CR168","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1750-1172-3-13","volume":"3","author":"A Sarkozy","year":"2008","unstructured":"Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. Orphanet J Rare Dis. 2008;3:13.","journal-title":"Orphanet J Rare Dis"},{"key":"517_CR169","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1172\/JCI43910","volume":"120","author":"PC Chen","year":"2010","unstructured":"Chen PC, Wakimoto H, Conner D, Araki T, Yuan T, Roberts A, Seidman C, Bronson R, Neel B, Seidman JG, et al. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J Clin Invest. 2010;120:4353\u201365.","journal-title":"J Clin Invest"},{"key":"517_CR170","doi-asserted-by":"publisher","first-page":"15436","DOI":"10.1073\/pnas.0903302106","volume":"106","author":"T Nakamura","year":"2009","unstructured":"Nakamura T, Gulick J, Pratt R, Robbins J. Noonan syndrome is associated with enhanced pERK activity, the repression of which can prevent craniofacial malformations. Proc Natl Acad Sci U S A. 2009;106:15436\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR171","doi-asserted-by":"publisher","first-page":"16395","DOI":"10.1073\/pnas.1418126111","volume":"111","author":"I Hernandez-Porras","year":"2014","unstructured":"Hernandez-Porras I, Fabbiano S, Schuhmacher AJ, Aicher A, Canamero M, Camara JA, Cusso L, Desco M, Heeschen C, Mulero F, et al. K-RasV14I recapitulates Noonan syndrome in mice. Proc Natl Acad Sci U S A. 2014;111:16395\u2013400.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR172","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1172\/JCI44929","volume":"121","author":"X Wu","year":"2011","unstructured":"Wu X, Simpson J, Hong JH, Kim KH, Thavarajah NK, Backx PH, Neel BG, Araki T. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest. 2011;121:1009\u201325.","journal-title":"J Clin Invest"},{"key":"517_CR173","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.1073\/pnas.0810053106","volume":"106","author":"T Araki","year":"2009","unstructured":"Araki T, Chan G, Newbigging S, Morikawa L, Bronson RT, Neel BG. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A. 2009;106:4736\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR174","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1073\/pnas.1508535113","volume":"113","author":"X Liu","year":"2016","unstructured":"Liu X, Zheng H, Li X, Wang S, Meyerson HJ, Yang W, Neel BG, Qu CK. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies. Proc Natl Acad Sci U S A. 2016;113:984\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR175","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1210\/jc.2003-032091","volume":"89","author":"R Yoshida","year":"2004","unstructured":"Yoshida R, Hasegawa T, Hasegawa Y, Nagai T, Kinoshita E, Tanaka Y, Kanegane H, Ohyama K, Onishi T, Hanew K, et al. Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocrinol Metab. 2004;89:3359\u201364.","journal-title":"J Clin Endocrinol Metab"},{"key":"517_CR176","doi-asserted-by":"publisher","first-page":"30984","DOI":"10.1074\/jbc.M504699200","volume":"280","author":"H Keilhack","year":"2005","unstructured":"Keilhack H, David FS, McGregor M, Cantley LC, Neel BG. Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes. J Biol Chem. 2005;280:30984\u201393.","journal-title":"J Biol Chem"},{"key":"517_CR177","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S0968-0004(03)00091-4","volume":"28","author":"BG Neel","year":"2003","unstructured":"Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28:284\u201393.","journal-title":"Trends Biochem Sci"},{"key":"517_CR178","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.tig.2003.11.003","volume":"20","author":"M Ernst","year":"2004","unstructured":"Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends Genet. 2004;20:23\u201332.","journal-title":"Trends Genet"},{"key":"517_CR179","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1006\/excr.1999.4668","volume":"253","author":"GS Feng","year":"1999","unstructured":"Feng GS. Shp-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res. 1999;253:47\u201354.","journal-title":"Exp Cell Res"},{"key":"517_CR180","first-page":"1251","volume":"22","author":"ZZ Chong","year":"2007","unstructured":"Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007;22:1251\u201367.","journal-title":"Histol Histopathol"},{"key":"517_CR181","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1161\/CIRCRESAHA.108.179754","volume":"103","author":"TM Marin","year":"2008","unstructured":"Marin TM, Clemente CF, Santos AM, Picardi PK, Pascoal VD, Lopes-Cendes I, Saad MJ, Franchini KG. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase\/Src and mTOR pathways. Circ Res. 2008;103:813\u201324.","journal-title":"Circ Res"},{"key":"517_CR182","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1006\/scel.1993.1050","volume":"4","author":"BG Neel","year":"1993","unstructured":"Neel BG. Structure and function of SH2-domain containing tyrosine phosphatases. Semin Cell Biol. 1993;4:419\u201332.","journal-title":"Semin Cell Biol"},{"key":"517_CR183","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.cr.7290055","volume":"10","author":"CK Qu","year":"2000","unstructured":"Qu CK. The SHP-2 tyrosine phosphatase: signaling mechanisms and biological functions. Cell Res. 2000;10:279\u201388.","journal-title":"Cell Res"},{"key":"517_CR184","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1523\/JNEUROSCI.4364-09.2010","volume":"30","author":"Z Cai","year":"2010","unstructured":"Cai Z, Feng GS, Zhang X. Temporal requirement of the protein tyrosine phosphatase Shp2 in establishing the neuronal fate in early retinal development. J Neurosci. 2010;30:4110\u20139.","journal-title":"J Neurosci"},{"key":"517_CR185","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.braindev.2011.10.011","volume":"34","author":"YS Huang","year":"2012","unstructured":"Huang YS, Cheng CY, Chueh SH, Hueng DY, Huang YF, Chu CM, Wu ST, Tai MC, Liang CM, Liao MH, et al. Involvement of SHP2 in focal adhesion, migration and differentiation of neural stem cells. Brain and Development. 2012;34:674\u201384.","journal-title":"Brain and Development"},{"key":"517_CR186","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1471-4159.2010.06596.x","volume":"113","author":"E Kuo","year":"2010","unstructured":"Kuo E, Park DK, Tzvetanova ID, Leiton CV, Cho BS, Colognato H. Tyrosine phosphatases Shp1 and Shp2 have unique and opposing roles in oligodendrocyte development. J Neurochem. 2010;113:200\u201312.","journal-title":"J Neurochem"},{"key":"517_CR187","doi-asserted-by":"publisher","first-page":"e21058","DOI":"10.1371\/journal.pone.0021058","volume":"6","author":"X Liu","year":"2011","unstructured":"Liu X, Li Y, Zhang Y, Lu Y, Guo W, Liu P, Zhou J, Xiang Z, He C. SHP-2 promotes the maturation of oligodendrocyte precursor cells through Akt and ERK1\/2 signaling in vitro. PLoS One. 2011;6:e21058.","journal-title":"PLoS One"},{"key":"517_CR188","doi-asserted-by":"publisher","first-page":"16704","DOI":"10.1073\/pnas.0904336106","volume":"106","author":"KS Grossmann","year":"2009","unstructured":"Grossmann KS, Wende H, Paul FE, Cheret C, Garratt AN, Zurborg S, Feinberg K, Besser D, Schulz H, Peles E, et al. The tyrosine phosphatase Shp2 (PTPN11) directs Neuregulin-1\/ErbB signaling throughout Schwann cell development. Proc Natl Acad Sci U S A. 2009;106:16704\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR189","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1093\/hmg\/ddp186","volume":"18","author":"C Anastasaki","year":"2009","unstructured":"Anastasaki C, Estep AL, Marais R, Rauen KA, Patton EE. Kinase-activating and kinase-impaired cardio-facio-cutaneous syndrome alleles have activity during zebrafish development and are sensitive to small molecule inhibitors. Hum Mol Genet. 2009;18:2543\u201354.","journal-title":"Hum Mol Genet"},{"issue":"8","key":"517_CR190","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1038\/mp.2017.238","volume":"23","author":"E Yeh","year":"2017","unstructured":"Yeh E, Dao DQ, Wu ZY, Kandalam SM, Camacho FM, Tom C, Zhang W, Krencik R, Rauen KA, Ullian EM, et al. Patient-derived iPSCs show premature neural differentiation and neuron type-specific phenotypes relevant to neurodevelopment. Mol Psychiatry. 2017;23(8):1687\u201398.","journal-title":"Molecular Psychiatry"},{"key":"517_CR191","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/glia.20845","volume":"57","author":"TH Yeh","year":"2009","unstructured":"Yeh TH, Lee DY, Gianino SM, Gutmann DH. Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. Glia. 2009;57:1239\u201349.","journal-title":"Glia."},{"key":"517_CR192","doi-asserted-by":"publisher","first-page":"7349","DOI":"10.1093\/hmg\/ddv435","volume":"24","author":"M Moriya","year":"2015","unstructured":"Moriya M, Inoue S, Miyagawa-Tomita S, Nakashima Y, Oba D, Niihori T, Hashi M, Ohnishi H, Kure S, Matsubara Y, et al. Adult mice expressing a Braf Q241R mutation on an ICR\/CD-1 background exhibit a cardio-facio-cutaneous syndrome phenotype. Hum Mol Genet. 2015;24:7349\u201360.","journal-title":"Hum Mol Genet"},{"key":"517_CR193","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/83960","volume":"4","author":"S Wiese","year":"2001","unstructured":"Wiese S, Pei G, Karch C, Troppmair J, Holtmann B, Rapp UR, Sendtner M. Specific function of B-Raf in mediating survival of embryonic motoneurons and sensory neurons. Nat Neurosci. 2001;4:137\u201342.","journal-title":"Nat Neurosci"},{"key":"517_CR194","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/ng0797-293","volume":"16","author":"L Wojnowski","year":"1997","unstructured":"Wojnowski L, Zimmer AM, Beck TW, Hahn H, Bernal R, Rapp UR, Zimmer A. Endothelial apoptosis in Braf-deficient mice. Nat Genet. 1997;16:293\u20137.","journal-title":"Nat Genet"},{"key":"517_CR195","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/jnr.20703","volume":"83","author":"AP Chen","year":"2006","unstructured":"Chen AP, Ohno M, Giese KP, Kuhn R, Chen RL, Silva AJ. Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory. J Neurosci Res. 2006;83:28\u201338.","journal-title":"J Neurosci Res"},{"key":"517_CR196","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1101\/gad.193458.112","volume":"26","author":"C Andreadi","year":"2012","unstructured":"Andreadi C, Cheung LK, Giblett S, Patel B, Jin H, Mercer K, Kamata T, Lee P, Williams A, McMahon M, et al. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF\/MEK\/ERK pathway. Genes Dev. 2012;26:1945\u201358.","journal-title":"Genes Dev"},{"key":"517_CR197","doi-asserted-by":"publisher","first-page":"6553","DOI":"10.1093\/hmg\/ddu376","volume":"23","author":"S Inoue","year":"2014","unstructured":"Inoue S, Moriya M, Watanabe Y, Miyagawa-Tomita S, Niihori T, Oba D, Ono M, Kure S, Ogura T, Matsubara Y, et al. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome. Hum Mol Genet. 2014;23:6553\u201366.","journal-title":"Hum Mol Genet"},{"key":"517_CR198","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/ajmg.a.33884","volume":"155a","author":"KW Gripp","year":"2011","unstructured":"Gripp KW, Hopkins E, Sol-Church K, Stabley DL, Axelrad ME, Doyle D, Dobyns WB, Hudson C, Johnson J, Tenconi R, et al. Phenotypic analysis of individuals with Costello syndrome due to HRAS p.G13C. Am J Med Genet A. 2011;155a:706\u201316.","journal-title":"Am J Med Genet A"},{"key":"517_CR199","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/ajmg.a.35292","volume":"158a","author":"Y Abe","year":"2012","unstructured":"Abe Y, Aoki Y, Kuriyama S, Kawame H, Okamoto N, Kurosawa K, Ohashi H, Mizuno S, Ogata T, Kure S, et al. Prevalence and clinical features of Costello syndrome and cardio-facio-cutaneous syndrome in Japan: findings from a nationwide epidemiological survey. Am J Med Genet A. 2012;158a:1083\u201394.","journal-title":"Am J Med Genet A"},{"key":"517_CR200","first-page":"114","volume":"13","author":"JM Costello","year":"1977","unstructured":"Costello JM. A new syndrome: mental subnormality and nasal papillomata. Aust Paediatr J. 1977;13:114\u20138.","journal-title":"Aust Paediatr J"},{"key":"517_CR201","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.a.31047","volume":"140","author":"KW Gripp","year":"2006","unstructured":"Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI Jr, Doyle D, Aoki Y, Matsubara Y, Zackai EH, Lapunzina P, et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A. 2006;140:1\u20137.","journal-title":"Am J Med Genet A"},{"key":"517_CR202","doi-asserted-by":"publisher","first-page":"5704","DOI":"10.1073\/pnas.81.18.5704","volume":"81","author":"JB Gibbs","year":"1984","unstructured":"Gibbs JB, Sigal IS, Poe M, Scolnick EM. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A. 1984;81:5704\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"517_CR203","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10038-007-0146-1","volume":"52","author":"DR Bertola","year":"2007","unstructured":"Bertola DR, Pereira AC, Brasil AS, Albano LM, Kim CA, Krieger JE. Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene. J Hum Genet. 2007;52:521\u20136.","journal-title":"J Hum Genet"},{"key":"517_CR204","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/gim.0b013e31822dd91f","volume":"14","author":"KW Gripp","year":"2012","unstructured":"Gripp KW, Lin AE. Costello syndrome: a Ras\/mitogen activated protein kinase pathway syndrome (rasopathy) resulting from HRAS germline mutations. Genet Med. 2012;14:285\u201392.","journal-title":"Genet Med"},{"key":"517_CR205","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/ajmg.a.33857","volume":"155a","author":"AE Lin","year":"2011","unstructured":"Lin AE, Alexander ME, Colan SD, Kerr B, Rauen KA, Noonan J, Baffa J, Hopkins E, Sol-Church K, Limongelli G, et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras\/MAPK pathway syndrome. Am J Med Genet A. 2011;155a:486\u2013507.","journal-title":"Am J Med Genet A"},{"key":"517_CR206","doi-asserted-by":"publisher","first-page":"286ra66","DOI":"10.1126\/scitranslmed.aaa5645","volume":"7","author":"R Krencik","year":"2015","unstructured":"Krencik R, Hokanson KC, Narayan AR, Dvornik J, Rooney GE, Rauen KA, Weiss LA, Rowitch DH, Ullian EM. Dysregulation of astrocyte extracellular signaling in Costello syndrome. Sci Transl Med. 2015;7:286ra66.","journal-title":"Sci Transl Med"},{"key":"517_CR207","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1523\/JNEUROSCI.1547-15.2016","volume":"36","author":"GE Rooney","year":"2016","unstructured":"Rooney GE, Goodwin AF, Depeille P, Sharir A, Schofield CM, Yeh E, Roose JP, Klein OD, Rauen KA, Weiss LA, et al. Human iPS Cell-Derived Neurons Uncover the Impact of Increased Ras Signaling in Costello Syndrome. J Neurosci. 2016;36:142\u201352.","journal-title":"J Neurosci"},{"key":"517_CR208","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/ajmg.a.33391","volume":"152a","author":"KW Gripp","year":"2010","unstructured":"Gripp KW, Hopkins E, Doyle D, Dobyns WB. High incidence of progressive postnatal cerebellar enlargement in Costello syndrome: brain overgrowth associated with HRAS mutations as the likely cause of structural brain and spinal cord abnormalities. Am J Med Genet A. 2010;152a:1161\u20138.","journal-title":"Am J Med Genet A"},{"key":"517_CR209","first-page":"2169","volume":"118","author":"AJ Schuhmacher","year":"2008","unstructured":"Schuhmacher AJ, Guerra C, Sauzeau V, Canamero M, Bustelo XR, Barbacid M. A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest. 2008;118:2169\u201379.","journal-title":"J Clin Invest"},{"key":"517_CR210","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1601-183X.2008.00443.x","volume":"8","author":"J Viosca","year":"2009","unstructured":"Viosca J, Schuhmacher AJ, Guerra C, Barco A. Germline expression of H-Ras(G12V) causes neurological deficits associated to Costello syndrome. Genes Brain Behav. 2009;8:60\u201371.","journal-title":"Genes Brain Behav"},{"key":"517_CR211","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.ydbio.2009.04.010","volume":"330","author":"A Paquin","year":"2009","unstructured":"Paquin A, Hordo C, Kaplan DR, Miller FD. Costello syndrome H-Ras alleles regulate cortical development. Dev Biol. 2009;330:440\u201351.","journal-title":"Dev Biol"},{"key":"517_CR212","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/aja.1001950307","volume":"195","author":"MM Daston","year":"1992","unstructured":"Daston MM, Ratner N. Neurofibromin, a predominantly neuronal GTPase activating protein in the adult, is ubiquitously expressed during development. Dev Dyn. 1992;195:216\u201326.","journal-title":"Dev Dyn"},{"key":"517_CR213","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/jama.300.3.287","volume":"300","author":"LC Krab","year":"2008","unstructured":"Krab LC, de Goede-Bolder A, Aarsen FK, Pluijm SM, Bouman MJ, van der Geest JN, Lequin M, Catsman CE, Arts WF, Kushner SA, et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. Jama. 2008;300:287\u201394.","journal-title":"Jama."},{"key":"517_CR214","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S1474-4422(13)70227-8","volume":"12","author":"T van der Vaart","year":"2013","unstructured":"van der Vaart T, Plasschaert E, Rietman AB, Renard M, Oostenbrink R, Vogels A, de Wit MC, Descheemaeker MJ, Vergouwe Y, Catsman-Berrevoets CE, et al. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial. Lancet Neurol. 2013;12:1076\u201383.","journal-title":"Lancet Neurol"},{"key":"517_CR215","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1212\/WNL.0000000000003435","volume":"87","author":"JM Payne","year":"2016","unstructured":"Payne JM, Barton B, Ullrich NJ, Cantor A, Hearps SJ, Cutter G, Rosser T, Walsh KS, Gioia GA, Wolters PL, et al. Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016;87:2575\u201384.","journal-title":"Neurology."},{"key":"517_CR216","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13229-018-0190-z","volume":"9","author":"S Stivaros","year":"2018","unstructured":"Stivaros S, Garg S, Tziraki M, Cai Y, Thomas O, Mellor J, Morris AA, Jim C, Szumanska-Ryt K, Parkes LM, et al. Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA). Molecular autism. 2018;9:12.","journal-title":"Molecular autism"},{"key":"517_CR217","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/mp.2015.48","volume":"20","author":"A Omrani","year":"2015","unstructured":"Omrani A, van der Vaart T, Mientjes E, van Woerden GM, Hojjati MR, Li KW, Gutmann DH, Levelt CN, Smit AB, Silva AJ, et al. HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1. Mol Psychiatry. 2015;20:1311\u201321.","journal-title":"Mol Psychiatry"},{"key":"517_CR218","doi-asserted-by":"publisher","first-page":"R909","DOI":"10.1016\/j.cub.2018.07.046","volume":"28","author":"JR Howe","year":"2018","unstructured":"Howe JR, Bear MF, Golshani P, Klann E, Lipton SA, Mucke L, Sahin M, Silva AJ. The mouse as a model for neuropsychiatric drug development. Curr Biol. 2018;28:R909\u2013R14.","journal-title":"Curr Biol"}],"container-title":["Molecular Brain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-019-0517-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13041-019-0517-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13041-019-0517-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T16:20:38Z","timestamp":1665073238000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularbrain.biomedcentral.com\/articles\/10.1186\/s13041-019-0517-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":218,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1186\/s13041-019-0517-5","relation":{},"ISSN":["1756-6606"],"issn-type":[{"value":"1756-6606","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}